IO Biotech Inc
IOBT
Detailliertes Diagramm anzeigen
0.890USD
+0.051+6.09%
Handelsschluss 11/05, 16:00（ET）Kurse um 15 Minuten verzögert
58.62MMarktkapitalisierung
VerlustKGV TTM
Intraday
1m
30m
1h
D
W
M
D
Heute
+6.09%
5 Tage
+1.74%
1 Monat
+84.61%
6 Monate
-21.95%
Seit Jahresbeginn
-3.28%
1 Jahr
-22.63%
Detailliertes Diagramm anzeigen
TradingKey Aktienbewertung von IO Biotech Inc
Währung: USD Aktualisiert: 2025-10-27Wichtige Einblicke
Seine Bewertung wird als unterbewertet angesehen,und die institutionelle Anerkennung ist sehr hoch. In den letzten 30 Tagen haben mehrere Analysten die Aktie mit einer Kaufen bewertet. Der Aktienkurs bewegt sich seitwärts zwischen den Unterstützungs- und Widerstandsniveaus, was ihn für schwankungsorientiertes Trading geeignet macht.
IO Biotech Inc Bewertung
Widerstand & Unterstützung
Keine Daten
Radar Chart
Aktueller Preis
Vorher
Analysten-Ziel
Basierend auf insgesamt
6
Analysten
Kaufen
Aktuelles Rating
2.463
Kursziel
+193.71%
Aufwärtspotenzial
Hinweis: Analystenbewertungen und Kursziele werden von LSEG ausschließlich zu Informationszwecken bereitgestellt und stellen keine Anlageberatung dar.
IO Biotech Inc Highlights
HöhepunkteRisiko
IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.
high_profit_growth
high_profit_growth_desc%!(EXTRA string=0.00)
valuation_overestimated
valuation_overestimated_desc%!(EXTRA string=PE, string=-0.58)
institutional_decreasing_position
institutional_decreasing_position_desc%!(EXTRA string=42.06M, string=24.13%)
institutional_hold%!(EXTRA string=James Simons)
institutional_hold_desc%!(EXTRA string=James Simons, string=139.30K)
activity_increase
activity_increase_desc%!(EXTRA string=13.93)
IO Biotech Inc Nachrichten
Bald gibt es mehr Neuigkeiten, bleiben Sie dran...
Finanzindikatoren
EPS
Keine Daten
Gesamteinnahmen
Keine Daten
IO Biotech Inc Informationen
IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.
BörsenkürzelIOBT
UnternehmenIO Biotech Inc
CEODr. Mai-Britt Zocca, Ph.D.
Websitehttps://www.iobiotech.com/
Verwandte Finanzinstrumente
+2.09%
-0.46%
+0.41%
-1.07%
+0.39%
+0.63%
+7.81%
+0.44%
-0.34%
+1.28%
-0.22%
-1.11%
+0.31%
+1.93%
-0.28%
-0.11%
0.00%
+2.58%
+2.62%
-3.19%Beliebte Symbole
